Humana and Centene Corporation filed suit against Merck, alleging that the drugmaker ran a "monopolistic scheme" to delay generic challengers to its cholesterol medications Zetia and Vytorin. In the ...

The FINANCIAL — Teva Pharmaceutical Industries Ltd., on June 12 announced the launch of generic Zetia®1 (ezetimibe) tablets, 10 mg, in the U.S. Ezetimibe is a prescription medicine used to lower ...

Obicetrapib, a Lazarus-like cholesteryl ester transfer protein (CETP) inhibitor currently on its second life, checked another box in its development program with investigators showing the drug could ...

Kaiser Foundation Health Plans is suing Merck alleging anticompetitive behavior for delaying a generic version of its drug to enter the market, a practice known in the industry as "pay-for-delay." ...

Kaiser Permanente's health plan has filed suit against Merck and the company manufacturing generics of two of its popular products over delays in the launch of those generics. Kaiser Foundation Health ...

Please provide your email address to receive an email when new articles are posted on . Obicetrapib plus ezetimibe lowered LDL nearly 50% vs. placebo in patients with high atherosclerotic risk.

Centene and Humana filed similar lawsuits against Merck and Glenmark on the same day, alleging a pay-for-delay scheme they claim Merck used to protect billions in profits from generic competition. The ...

Zetia, or ezetimibe, is a duration-lowering medication that effects differently than statin cholesterol medications. Statins devil to lower cholesterol by inhibiting its site in the pancreas. Zetia ...

Thirteen years after the fact, a copycat accord with Glenmark Pharmaceuticals has come back to haunt Merck & Co. And now, the alleged pay-for-delay collaborators must face a jury trial. Late last week ...